Targeting IL-17RB and MCT 2 to treat breast cancer may be possible
The Genetic Materials Research Center at Taiwan’s Academia Sinica reports two new possibilities in treating breast cancer by developing an antibody of the IL-17RB gene and medication targeting the MCT 2 gene.
When breast tumor cells enter the lymph nodes, the TGF-beta 1 factor, a polypeptide of TGF (transforming growth factor Beta of the super family of cytokines), secreted by Tregs (regulatory T cells) will activate the IL-17RB (Interleukin 17 Receptor B) cells and help the growth of the breast tumor cells. The secretion of the TGF-beta 1 factor will also increase toxicity of the breast cancer cells and increase the possibility of migratory transfer of the cancer cells. Among breast cancer patients, 20% to 25% carry the IL-17RB gene.
The research team also discovered that lipocytes (adipocytes) also promote malignant growth of breast tumors with monocarboxylate transporter 2 (MCT 2) expression via Beta-hydroxybutyrate. In future, it may be possible to develop medications targeting the MCT 2 in breast cancer treatment.